Why Are Investors Ignoring Vertex's Good News?

Why Are Investors Ignoring Vertex's Good News?
·4 min read

Vertex Pharmaceuticals' (NASDAQ: VRTX) woes began about a year ago when it announced the failure of an alpha-1 antitrypsin deficiency (AATD) candidate in clinical trials. Since that first problem, Vertex shares have dropped 33%. Vertex boasts a billion-dollar cystic fibrosis (CF) business.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting